Abstract |
Formol sublimate-fixed cell blocks derived from 129 malignant pleural (and some peritoneal) effusions, 8 benign effusions with reactive mesothelial cells, and 23 FNA specimens, were immunostained with monoclonal antibody Ber-EP4 to assess its ability to distinguish malignant mesothelioma (MM) from carcinoma. Only 2 of 44 (4%) well-characterized MM were Ber-EP4+, while none of 8 benign mesothelial proliferations reacted with the antibody. Fifty-seven percent of 23 pulmonary adenocarcinomas (AC) and 60% of 43 pulmonary carcinomas of all other histological types were Ber-EP4+. Of 40 metastatic AC originating from breast, gastrointestinal tract, ovary, endometrium, and kidney, 80% were Ber-EP4+. The predictive value of positive Ber-EP4 staining in distinguishing AC from MM was 96%. The predictive value of a negative Ber-EP4 in excluding MM was 70%, when the differential diagnosis was adenocarcinoma. These results suggest that Ber-EP4 is helpful in differentiating MM and AC if used together with other discriminating antibodies.
|
Authors | B Maguire, D Whitaker, S Carrello, D Spagnolo |
Journal | Diagnostic cytopathology
(Diagn Cytopathol)
Vol. 10
Issue 2
Pg. 130-4
( 1994)
ISSN: 8755-1039 [Print] United States |
PMID | 8187591
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Antibodies, Monoclonal
- Ascitic Fluid
(pathology)
- Biopsy, Needle
- Carcinoma
(pathology, secondary)
- Humans
- Lung Neoplasms
(pathology)
- Mesothelioma
(pathology)
- Peritoneal Neoplasms
(pathology, secondary)
- Pleural Effusion, Malignant
(pathology)
- Pleural Neoplasms
(pathology, secondary)
|